Amanote Research
Register
Sign In
Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukaemia
Hematological Oncology
- United Kingdom
doi 10.1002/hon.2439_148
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2017
Authors
K. Mason
C. Sharpe
J. Davis
R. Koldej
C. Tam
D. Ritchie
Publisher
Wiley
Related search
Disseminated Mucormycosis Due to Lichtheimia Corymbifera During Ibrutinib Treatment for Relapsed Chronic Lymphocytic Leukaemia: A Case Report
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Unravelling the Suboptimal Response of TP53 -Mutated Chronic Lymphocytic Leukaemia to Ibrutinib
British Journal of Haematology
Hematology
VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (Literature Review)
Oncogematologiya
Oncology
Hematology
Lack of Adequate Pneumococcal Vaccination Response in Chronic Lymphocytic Leukaemia Patients Receiving Ibrutinib
British Journal of Haematology
Hematology
Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Comparative Analysis of Targeted Novel Therapies in Relapsed, Refractory Chronic Lymphocytic Leukaemia
Haematologica
Hematology
Addition of Venetoclax at Time of Progression in Ibrutinib‐treated Patients With Chronic Lymphocytic Leukemia: Combination Therapy to Prevent Ibrutinib Flare
American Journal of Hematology
Hematology
Chronic Lymphocytic Leukaemia
Nature Reviews Disease Primers
Medicine
